Golimumab is a TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα.
- Mechanism
- Curator reviewed
As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFα. Inhibition of TNFα prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
- Primary indication
- Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) in patients 2 years old and above with active psoriatic arthritis (PsA), (iii) as...Curator reviewed · 8 structured indications
- Formula / weight
- C6530H10068N1752O2026S44 · 146943.1937 Da
- First approval
- Canada, 2013 · United States, 2009 · European Union, 2016
- Code names
- CNTO-148
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Golimumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account